Test Details: The KRAS mutation, which has been associated with several human cancers including lung adenocarcinomas, pancreatic cancers, gastric cancers, biliary cancers and colorectal cancers, is often an early event in tumorigenesis. The mutation of clinical significance are commonly observed in Exon 3-codon 61 and are frequent in colorectal carcinomas. The impact of KRAS mutation on the efficacy of therapies that target the epidermal growth factor (EGFR) is aimed at identifying the best possible treatments for individual colon cancer patients. Because patients with KRAS mutant colorectal tumor rarely respond to anti-EGFR monoclonal antibodies such as Erbitux. Testing is required to confirm if the patient’s tumor is KRAS wild type before utilizing these therapies. The anti-EGFR therapy in combination with the standard chemotherapy regime, is effective in metastatic colorectal cancer. However, the addition of such targeted therapies results in an increase in toxicity and treatment costs. Hence, in metastatic colorectal cancer, it is imperative to investigate the KRAS gene mutation.